中国实时数据基础设施及分析解决方案供应商迅策，开报48.02元，较招股价48元高开0.1%，每手100 股，一手帐面赚2元。 以18C章程申请上市的数字孪生科技公司五一视界，开报35元，较招股价30.5元高14.8%，每手200股， 一手帐面赚900元。 预制钢结构建筑服务公司美联股份开报8.21元，较招股价7.1元高15.6%，每手300股，一手帐面赚333 元。 这是港交所年内第二次再现"六锣齐鸣"盛况，上一次为7月9日。 港股IPO年末"混战"，六股首挂，五股高开！覆盖特专科技、AI、机器人、制药、传统制造、护肤等 热门赛道，合计预计募资近60亿港元。 AI制药平台英矽智能强势领涨！开报35港币，较招股价24.05元高45.5%，每手500股，一手帐面赚5475 元。 开发家庭机器人系统的卧安机器人表现相对逊色，开报73.8元，较招股价73.8元持平。 高端化妆品公司林清轩开报85元，较招股价77.77元高9.3%，每手50股，一手帐面赚361.5元。 来源：新浪港股 ...

A股结构性分化与改革深化A股2025年IPO募资额130宗、约1300亿元人民币（-28%），呈现"主板收缩、科创板/北交所扩容"特征：①科创板聚焦半导体（摩 尔线程80亿元、沐曦42亿元），北交所服务"专精特新"（24宗IPO）；②REITs成为稳定器（20宗上市，基础设施/房地产占比36%），但传统制造业（中策 橡胶41亿元）募资占比下滑；③监管强化"科创属性"审核，3家未盈利企业登陆科创板，凸显"硬科技"导向。展望2026年，证监会拟推出"科创成长层"，允 许未盈利企业带期权上市，并试点T+0交易与做市商制度，以对冲港股分流压力。 2026年展望与风险对冲香港市场有望延续"三引擎"增长：①A+H上市（316宗处理中申请，92家市值>100亿元企业排队）与第二上市（拼多多、字节跳动潜 在回流）；②特专科技（机器人、智能驾驶）与生物制药（18A章募资125亿港元）持续扩容；③中东与东南亚主权基金（沙特PIF、新加坡GIC）加大港股 配置，推动"离岸人民币+美元"双币发行。风险方面，需关注：①美联储政策反复导致外资撤离；②A股全面注册制下破发率上升（2025年创业板首日破发 率35%）；③地缘政治升级（如美国 ...

Core Insights - The Hong Kong IPO market has shown a strong recovery, with the listing of JD Industrial marking the 100th new stock in 2025, highlighting the market's resilience and attractiveness as an international financial center [1] Group 1: IPO Market Performance - In 2025, the Hong Kong IPO market raised over 270 billion HKD, significantly surpassing the previous year's figures and marking the second highest fundraising level in five years [2] - The Hong Kong Stock Exchange (HKEX) is projected to lead globally in fundraising with approximately 36 billion USD (about 280.8 billion HKD) in 2025, outpacing the New York Stock Exchange's expected 20.5 billion USD [2] - Eight new stocks raised over 10 billion HKD each, with CATL leading at 41.006 billion HKD, setting a record for the largest IPO globally this year [2] Group 2: Large IPOs and Sector Contributions - Large IPOs have been a key driver of the Hong Kong market's resurgence, with over 20 A-share companies expected to debut in Hong Kong, raising over 170 billion HKD collectively [3] - The average fundraising size has increased by 137% compared to last year, reaching the second highest level in five years, with industrial and retail sectors dominating [3] Group 3: Technology Sector Dominance - Technology-related companies have emerged as the main force in the IPO wave, particularly those under Chapter 18A (unprofitable biotech companies) and Chapter 18C (specialized technology companies) [3] - In 2025, 14 companies listed under Chapter 18A, a 250% increase from 2024, focusing on innovative fields such as cancer treatment and gene editing [4] Group 4: Market Outlook and Predictions - Major institutions are optimistic about the 2026 IPO market, predicting 150 to 200 new listings and fundraising exceeding 300 billion HKD [6] - UBS forecasts that the Hong Kong market will maintain its position as the top fundraising venue, with several large IPOs expected in January [6] Group 5: Recommendations for Companies - Companies planning to go public are advised to embrace technology and build integrated financial governance systems to ensure data transparency and compliance with regulatory standards [7]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：昊 日前，成都卡诺普机器人技术股份有限公司（以下称"卡诺普"或"卡诺普机器人"）向港交所递交上市申请，拟通过18C特专科技通道在港股主板上市。 值得注意的是，对比相关上市规则，2024年卡诺普营收2.34亿元，约合2.58亿港元，刚刚达到商业化公司2.5亿港元的上市门槛。 同时，公司研发支出0.36亿元，占营业收入比例为15.4%，这一数字与"研发开支占营运支出的比例不低于15%"的要求十分接近。事实上，公司研发支出比 例逐年下滑，并且多数核心专利取得时间在10年以前。 相较于埃斯顿等可比公司，卡诺普营收规模极小，但毛利率却逆势上升并在业内领先。今年上半年，公司实现扭亏，但政府补助占比一直偏高，海外收入占 比也不断下滑，未来业绩或再度承压。 此外，卡诺普经营现金流连续两年净流出，应付账款也显著增加，尽快搭乘特专科技通道的东风完成上市，似乎已迫在眉睫。 主要财务指标或刚刚"踩线" 研发占比逐年下滑、几无新获核心专利 日前，卡诺普机器人正式向港交所递交主板上市申请，按照计划，募资将用于加强公司的研发能力， ...

Core Viewpoint - Shanghai XianGong Intelligent Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange for the second time this year, with CICC as its sole sponsor [1]. Group 1: Company Overview - XianGong Intelligent is an intelligent robotics company focused on robot control systems, integrating supply chain resources to provide comprehensive robot solutions for real-world applications [1][4]. - The company aims to eliminate barriers to the development, acquisition, and use of intelligent robots by offering a one-stop solution that includes controllers, software, robots, and accessories [4]. Group 2: Market Position - The company leverages its market position and leading technology in robot control systems, referred to as the "robot brain," to enhance its offerings [1].

Group 1 - The core point of the article is that Shanghai XianGong Intelligent Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange for the second time this year, with China International Capital Corporation as its sole sponsor [1] - The company previously submitted its listing application on May 27 [1] - XianGong Intelligent focuses on robot control systems and aims to provide a one-stop robotic solution for development, acquisition, and usage in real-world scenarios [1][4] Group 2 - XianGong Intelligent offers a comprehensive solution that includes controllers, software, robots, and accessories, aiming to eliminate barriers to the development, acquisition, and use of intelligent robots [4] - All of the company's products are defined as specialized technology products under Chapter 18C of the listing rules [4]

Core Insights - The Hong Kong IPO market has seen a significant presence of biopharmaceutical companies, with most listing under the HKEX Chapter 18A for unprofitable biotech firms, achieving strong first-day performance with many stocks rising over 100% [1] - The geographical distribution of these listings is concentrated, with 13 out of 19 biopharmaceutical companies coming from the Yangtze River Delta region, which includes 7 from Jiangsu, 4 from Zhejiang, and 2 from Shanghai [1] - The Yangtze River Delta contributes 30% of the national biopharmaceutical output, 30% of drug sales, and 70% of domestically produced Class 1 new drugs, with an industry value exceeding 1 trillion [1] - Additionally, 6 companies have listed under HKEX Chapter 18C for specialized technology firms, with 3 of these from the Guangzhou-Shenzhen area [1] - Market analysis suggests that as new first-tier cities enhance their IPO cultivation efforts, combined with the Hong Kong market's inclination towards specialized technology sectors, future mainland IPOs are expected to exhibit a "core leading, multi-point blossoming" trend [1] - Local governments are encouraged to align their local industry characteristics with the demands of the Hong Kong stock market [1]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本聆訊後資料集全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 CiDi Inc. 希迪智駕科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立之股份有限公司） 的聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證 監會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本聆訊後資料集為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、其相關保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據與香港公司註冊處處長註 冊的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不引起本公司 ...

Core Insights - The report discusses the new paradigm of Hong Kong's capital markets driven by technological empowerment and institutional innovation, focusing on the trends and regulations for mainland companies planning to list in Hong Kong by 2025 [1][24]. Listing Pathways - The report highlights the suitability of H-share direct listings and red-chip indirect listings, with a trend towards A-share to H-share conversions. It emphasizes the importance of compliance issues related to VIE structure dismantling, H-share "full circulation," and offshore trust applications [2][18]. - The new regulatory framework established in 2023 has simplified the H-share listing process and optimized the "full circulation" mechanism, providing a more efficient cross-border financing path for large state-owned and mature private enterprises [18][24]. Practical Issues - The report identifies key legal issues for companies planning to list in Hong Kong, including the design of equity incentives, tax planning, and information disclosure, which are critical for executives to manage effectively [2][20]. - The Hong Kong Stock Exchange has introduced initiatives like the "Tech Company Fast Track" to enhance the attractiveness of the market for technology firms, aiming to facilitate their listing processes [2][10]. Hot Industries - The report categorizes key industries such as hard technology, biomedicine, and new consumption, each facing unique compliance challenges. Hard tech companies must navigate intellectual property and export control issues, while biomedicine firms focus on data security and human genetic resource protection [2][22]. - New consumption enterprises face multiple compliance tests, including third-party payment regulations and store licensing management, while domestic chain enterprises must pay attention to franchise compliance and fund management [2][22]. Market Dynamics - By 2025, Hong Kong's capital market is projected to regain its position as the world's top fundraising destination, with over 90% of the companies being from mainland China, driven by institutional innovations that facilitate access to global capital [1][24]. - The report emphasizes that the new regulatory environment and the establishment of a comprehensive filing system mark a significant shift in the cross-border listing landscape, enhancing the market's appeal for innovative enterprises [24].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 CiDi Inc. 希迪智駕科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、各保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據與香港公司註冊處處長註 冊的本公司招股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不引起本公司、各保薦人、 整體協調 ...